Gernandt & Danielsson advises in Orexo’s early voluntary redemption of its outstanding bond loan and in Orexo’s issue of new corporate bonds
Gernandt & Danielsson advises Orexo AB (publ) in Orexo’s early voluntary total redemption of Orexo’s senior unsecured callable floating rate bonds due in 2018 and in Orexo’s issue of new corporate bonds at an initial total amount of SEK 325 million, within a framework amount of SEK 500 million. The proceeds from the bond issue will be used towards, inter alia, the repayment of the outstanding bond loan and towards general corporate purposes. The Company has undertaken to list the bonds on the corporate bond list of Nasdaq Stockholm.
Orexo is a pharmaceutical company focusing on the treatment of opioid dependence and pain relief. Orexo’s main market is the American market for the treatment of opioid dependence. Orexo’s ordinary shares are listed on Nasdaq Stockholm.
Gernandt & Danielsson has advised the company’s financial advisors, Pareto Securities AB with a team consisting of partner Mikael Borg, Senior Associate Sofie Viktorsson and Associates Camilla Hedner and Sara Gannby. Orexo was advised by Advokatfirman Vinge.Print